---
title: Local Anesthetics
type: content
phase: 1
status: complete
priority: high
tags: [local-anesthetics, lidocaine, bupivacaine, sodium-channels, regional-anesthesia, LAST]
created: 2025-11-08
last_modified: 2025-11-08
---

# Local Anesthetics

## Introduction

Local anesthetics are drugs that reversibly block nerve conduction when applied locally to nerve tissue. They produce loss of sensation (anesthesia) and/or loss of pain perception (analgesia) in a localized area without loss of consciousness. These drugs are fundamental to dentistry, surgery, pain management, and procedural medicine.

## Mechanism of Action

### Sodium Channel Blockade

**Primary Mechanism**: Blockade of voltage-gated sodium (Na+) channels in neuronal membranes

**Process**:
1. Local anesthetic crosses nerve membrane (lipophilic uncharged form)
2. Inside cell, equilibrates to charged form (ionized, BH+)
3. Charged form binds to intracellular side of Na+ channel
4. Blocks Na+ influx during depolarization
5. Prevents action potential propagation
6. Blocks nerve conduction

**State-Dependent Blockade**:
- Preferentially bind **open and inactivated states** of Na+ channel
- Less affinity for rested/closed state
- **Use-dependence**: More block with repeated depolarizations
  - Explains preferential block of rapidly firing pain neurons

**Ionization and pKa**:
- Local anesthetics are weak bases (pKa 7.6-9.0)
- Exist in equilibrium: BH+ (charged) ⇌ B (uncharged) + H+
- Henderson-Hasselbalch equation governs ionization

```
pKa = pH + log([BH+]/[B])

Low pH (acidic, inflammation) → ↑ionized form → ↓penetration → ↓efficacy
High pH (alkaline) → ↑uncharged form → ↑penetration → ↑efficacy
```

**Clinical Relevance**:
- **Infected tissue** (low pH): Less effective (more ionized)
- **Alkalinization** (adding bicarbonate): Faster onset
- **Epinephrine** formulations: Acidic pH for stability → slower onset

### Differential Nerve Block

**Sensitivity to Block** (most to least sensitive):
1. **Small myelinated** (Aδ, Aγ): Pain, temperature
2. **Unmyelinated C fibers**: Pain, temperature, autonomic
3. **Small myelinated** (Aβ): Touch, pressure
4. **Large myelinated** (Aα): Motor, proprioception

**Clinical Sequence**:
1. **Sympathetic block**: Vasodilation, temperature sensation loss
2. **Loss of pain and temperature**: Pinprick, cold sensation
3. **Loss of proprioception**
4. **Loss of touch and pressure**
5. **Loss of motor function**: Last to go

**Recovery**: Reverse order (motor returns first, pain last)

**Mechanism**: 
- Small fibers have higher surface area:volume ratio
- Easier for drug to penetrate
- Myelinated fibers only need block at nodes of Ranvier

---

## Chemical Classification

### Ester Local Anesthetics

**Structure**: Aromatic ring - ester linkage - amine group

**Examples**:
- Cocaine
- Procaine (Novocain)
- Chloroprocaine
- Tetracaine
- Benzocaine (topical only)

**Metabolism**:
- **Plasma cholinesterase** (pseudocholinesterase, butyrylcholinesterase)
- Rapid hydrolysis in plasma
- Metabolites: **PABA** (para-aminobenzoic acid)

**Allergic Reactions**:
- **More common** than amides
- Usually due to PABA metabolite
- True allergy (Type I hypersensitivity)
- Cross-reactivity between esters

**Procaine Metabolite**:
- PABA inhibits sulfonamide antibiotics (competition)

### Amide Local Anesthetics

**Structure**: Aromatic ring - amide linkage - amine group

**Examples**:
- Lidocaine (Xylocaine)
- Bupivacaine (Marcaine)
- Ropivacaine (Naropin)
- Mepivacaine (Carbocaine)
- Prilocaine (Citanest)
- Articaine
- Levobupivacaine
- Etidocaine

**Metabolism**:
- **Hepatic** (cytochrome P450)
- Slower than esters
- Prolonged with liver disease
- Metabolites generally inactive (except prilocaine → o-toluidine)

**Allergic Reactions**:
- **Rare** (< 1%)
- Usually due to preservatives (methylparaben, metabisulfite)
- Less cross-reactivity

**Mnemonic to Differentiate**:
- **Amides**: Two "i"s in name (lidocaine, bupivacaine, mepivacaine, ropivacaine)
- **Esters**: One "i" (procaine, tetracaine, cocaine) - except benzocaine

---

## Properties Affecting Clinical Use

### Potency

**Determinant**: **Lipid solubility**
- ↑Lipid solubility → ↑potency
- More lipophilic → better penetration of nerve sheath and membrane

**Order of Potency** (relative to procaine = 1):
- **Bupivacaine**: 8-16x (most potent)
- **Tetracaine**: 8-16x
- **Etidocaine**: 6x
- **Ropivacaine**: 6x
- **Mepivacaine**: 2x
- **Lidocaine**: 2-4x
- **Prilocaine**: 2x
- **Procaine**: 1x (reference)
- **Chloroprocaine**: 1x

### Onset of Action

**Determinants**:
1. **pKa** (most important)
   - Lower pKa → more uncharged form at physiologic pH → faster penetration
   - Faster onset
2. **Concentration**: Higher → faster
3. **Dose**: Higher → faster
4. **Site of injection**: Vascularity, tissue pH
5. **Presence of vasoconstrictors**

**Order of Onset**:
- **Fast**: Lidocaine (pKa 7.7), mepivacaine (7.6), chloroprocaine (8.7 but high concentration)
- **Intermediate**: Prilocaine (7.9)
- **Slow**: Bupivacaine (8.1), ropivacaine (8.1), tetracaine (8.5)

**Clinical Note**: Despite high pKa, chloroprocaine has fast onset due to high concentrations used and rapid ester hydrolysis

### Duration of Action

**Determinants**:
1. **Protein binding** (most important)
   - ↑Protein binding → ↑duration
   - Binds to proteins in Na+ channel
2. **Lipid solubility**: ↑Lipophilicity → ↑tissue binding
3. **Vascularity** of injection site
4. **Presence of vasoconstrictor** (epinephrine)

**Order of Duration**:
- **Long** (4-8h): Bupivacaine (95% protein bound), ropivacaine, etidocaine, tetracaine
- **Intermediate** (1-3h): Lidocaine (65%), mepivacaine (75%), prilocaine
- **Short** (15-45 min): Procaine (6%), chloroprocaine

---

## Individual Agents

### Lidocaine (Xylocaine)

**Classification**: Amide

**Characteristics**:
- Most widely used local anesthetic
- **Prototype** amide agent
- Intermediate potency, onset, duration

**Pharmacokinetics**:
- pKa: 7.7 (fastest amide onset)
- Protein binding: 65%
- Hepatic metabolism (CYP3A4, CYP1A2)
- Half-life: 1.5-2 hours

**Formulations**:
- Injectable: 0.5%, 1%, 1.5%, 2% (with or without epinephrine)
- Topical: Cream, gel, spray, ointment
- Transdermal: Lidocaine patch 5%

**Clinical Uses**:

1. **Local/Regional Anesthesia**:
   - Infiltration, nerve blocks
   - With epi: Duration 2-6 hours
   - Without epi: Duration 1-2 hours

2. **Topical Anesthesia**:
   - Mucous membranes (oropharynx, urethra, anorectal)
   - Skin (with prilocaine as EMLA cream)

3. **IV Regional Anesthesia** (Bier block):
   - Used without epinephrine
   - Tourniquet prevents systemic absorption

4. **Antiarrhythmic** (Class Ib):
   - Ventricular arrhythmias (VT, VF)
   - Loading: 1-1.5 mg/kg IV bolus
   - Infusion: 1-4 mg/min

**Maximum Doses**:
- **Without epinephrine**: 4.5 mg/kg (max 300 mg)
- **With epinephrine**: 7 mg/kg (max 500 mg)

**Adverse Effects**: See systemic toxicity below

### Bupivacaine (Marcaine)

**Classification**: Amide

**Characteristics**:
- **Longest duration** of commonly used agents
- **Most cardiotoxic** local anesthetic
- Racemic mixture (R and S enantiomers)

**Pharmacokinetics**:
- pKa: 8.1 (slower onset)
- Protein binding: 95% (longest duration)
- Lipid solubility: High (8x procaine)
- Hepatic metabolism
- Half-life: 2.7 hours

**Formulations**:
- 0.25%, 0.5%, 0.75% (with or without epinephrine)
- **0.75% contraindicated for obstetric anesthesia** (cardiotoxicity risk)

**Clinical Uses**:

1. **Long-duration infiltration/blocks**:
   - Surgical anesthesia: 0.5-0.75%
   - Postoperative analgesia: 0.25%

2. **Epidural**:
   - Labor analgesia: 0.0625-0.125% (often with fentanyl)
   - Surgical: 0.5-0.75%

3. **Spinal**:
   - 0.5-0.75% (hyperbaric or isobaric)

**Duration**:
- With epi: 4-8 hours
- Without epi: 2-4 hours

**Maximum Doses**:
- **Without epinephrine**: 2.5 mg/kg (max 175 mg)
- **With epinephrine**: 3 mg/kg (max 225 mg)

**Cardiotoxicity**:
- Rapid, profound cardiovascular collapse possible
- Mechanism: Myocardial Na+ and Ca2+ channel blockade
- **Difficult to resuscitate** (binds tightly to cardiac channels)
- **S-enantiomer less cardiotoxic** → levobupivacaine developed

**Motor vs. Sensory Block**:
- **Differential block** at low concentrations
- 0.125%: Sensory > motor (useful for labor analgesia)
- 0.5-0.75%: Motor and sensory

### Ropivacaine (Naropin)

**Classification**: Amide (pure S-enantiomer)

**Development**: Designed to be less cardiotoxic than bupivacaine

**Characteristics**:
- **Less cardiotoxic** than bupivacaine
- **Less motor block** than bupivacaine (at equivalent doses)
- Intrinsic vasoconstrictor properties

**Pharmacokinetics**:
- pKa: 8.1
- Protein binding: 94%
- Similar to bupivacaine but less lipophilic

**Clinical Uses**:
- Same as bupivacaine
- Preferred for epidural infusions (less motor block)

**Formulations**: 0.2%, 0.5%, 0.75%, 1%

**Maximum Dose**: 3 mg/kg (single injection)

**Advantages**:
- Safer than bupivacaine (wider therapeutic index)
- Better for epidural analgesia (minimal motor block at 0.2%)

### Levobupivacaine

**Classification**: Pure S-enantiomer of bupivacaine

**Advantages**:
- **30-50% less cardiotoxic** than racemic bupivacaine
- Similar efficacy, duration

**Use**: Alternative to bupivacaine where available

### Mepivacaine (Carbocaine)

**Classification**: Amide

**Characteristics**:
- Similar to lidocaine
- Slightly longer duration
- Intrinsic vasoconstrictor activity (less need for epinephrine)

**Pharmacokinetics**:
- pKa: 7.6 (fast onset)
- Protein binding: 75%

**Clinical Uses**:
- Dental procedures (very common)
- Regional anesthesia

**Maximum Dose**: 4.5 mg/kg (7 mg/kg with epi)

**Advantage**: Can use without epinephrine and still get reasonable duration

### Prilocaine (Citanest)

**Classification**: Amide

**Characteristics**:
- Least systemic toxicity (rapid distribution, low CNS toxicity)
- Used in higher doses than lidocaine

**Unique Adverse Effect**:
- **Methemoglobinemia**
- Metabolite: o-toluidine oxidizes hemoglobin (Fe2+ → Fe3+)
- Dose-related (>600 mg)
- **Treatment**: Methylene blue 1-2 mg/kg IV

**Clinical Uses**:
1. **EMLA cream** (eutectic mixture of local anesthetics)
   - Prilocaine 2.5% + lidocaine 2.5%
   - Topical anesthesia for intact skin
   - Apply 60-120 min before procedure
   - Used for venipuncture (children), minor procedures

2. **IV regional anesthesia** (Bier block)
   - Less toxic than lidocaine

3. **Dental procedures**

**Maximum Dose**: 8 mg/kg (highest of all agents due to low toxicity)

### Chloroprocaine (Nesacaine)

**Classification**: Ester

**Characteristics**:
- **Fastest onset** of all local anesthetics (despite high pKa)
- **Shortest duration**
- **Lowest systemic toxicity** (rapid plasma hydrolysis)

**Pharmacokinetics**:
- pKa: 8.7
- Rapid plasma esterase metabolism (half-life 25 seconds!)

**Clinical Uses**:
1. **Epidural anesthesia**: Especially obstetric (very safe)
2. **Infiltration**: When short duration needed

**Advantages**:
- Safest for pregnancy (minimal fetal exposure due to rapid metabolism)
- Can use large doses (low systemic toxicity)

**Maximum Dose**: 11 mg/kg (without epi), 14 mg/kg (with epi)

**Historical Issue**: Old formulations with bisulfite preservative caused neural toxicity; modern formulations safe

### Procaine (Novocain)

**Classification**: Ester (prototype ester)

**Characteristics**:
- **Historical significance** (first synthetic local anesthetic, 1905)
- Low potency
- Short duration
- **Rarely used now** (replaced by lidocaine)

**Maximum Dose**: 10 mg/kg (14 mg/kg with epi)

**Metabolism**: Plasma esterases → PABA (allergenic)

### Tetracaine (Pontocaine)

**Classification**: Ester

**Characteristics**:
- High potency (8-16x procaine)
- Long duration
- Slow onset
- **High systemic toxicity**

**Clinical Uses**:
1. **Spinal anesthesia**: Most common use
   - 5-20 mg (depending on level, duration needed)
   - Hyperbaric (with dextrose) or isobaric

2. **Topical**: Eye drops (ophthalmology)

**Advantages**: Long duration for spinal
**Disadvantages**: Toxic if absorbed systemically; slow onset

### Cocaine

**Classification**: Ester

**Unique Property**: **Only local anesthetic with intrinsic vasoconstrictor activity**
- Blocks norepinephrine reuptake → vasoconstriction

**Clinical Uses**:
1. **Topical anesthesia**: Nose, throat, ear (ENT procedures)
   - 4% solution
   - Provides anesthesia AND hemostasis
2. NOT used for infiltration or blocks (too toxic)

**Pharmacology**:
- CNS stimulant (blocks DA, NE, 5-HT reuptake)
- Abuse potential (Schedule II controlled substance)

**Toxicity**: See toxicity section

**Maximum Dose**: 3 mg/kg (200 mg total)

**Largely replaced** by combination of lidocaine + epinephrine for topical use

### Benzocaine

**Classification**: Ester

**Unique**: No ionizable amine group (always uncharged)

**Use**: **Topical only** (doesn't penetrate intact skin well)
- Sprays (Cetacaine, Hurricaine)
- Lozenges (sore throat)
- Teething gels

**Adverse Effect**: **Methemoglobinemia** (like prilocaine)
- FDA warning (2011, 2018)
- Especially in infants
- Treatment: Methylene blue

---

## Additives: Vasoconstrictors

### Epinephrine

**Concentrations**:
- 1:100,000 (10 mcg/mL) - most common
- 1:200,000 (5 mcg/mL)
- 1:400,000 (2.5 mcg/mL)

**Mechanism**: α1-mediated vasoconstriction → ↓blood flow

**Benefits**:
1. **Prolongs duration** (↓systemic absorption):
   - Lidocaine: 1h → 2-6h
   - Bupivacaine: Less effect (already long-acting)
2. **Reduces systemic toxicity** (slower absorption → lower peak plasma levels)
3. **Allows higher maximum doses** (see dosing above)
4. **Decreases surgical bleeding** (local vasoconstriction)
5. **Intensifies block** (higher local concentration)

**Contraindications**:
- **Digital blocks** (fingers, toes, penis, nose, ears)
  - Risk of ischemia and necrosis (end-arteries, no collaterals)
  - **NEVER use epinephrine in these areas**
- IV regional anesthesia (Bier block)
- Severe hypertension, coronary disease (relative)
- Concurrent use of MAOIs, TCAs (potentiate epinephrine)

**Adverse Effects**:
- Anxiety, tremor, palpitations
- Hypertension, tachycardia
- May delay wound healing (vasoconstriction)

**Epinephrine Test Dose**:
- 15 mcg epinephrine (3 mL of 1:200,000)
- Tests for intravascular injection
- Positive: ↑HR by 20 bpm within 60 seconds
- Used before large epidural doses

### Other Vasoconstrictors

**Phenylephrine**: Used in dentistry (avoid in cardiac patients)

**Vasopressin**: Rarely used

---

## Routes of Administration

### Topical Anesthesia

**Mucous Membranes**:
- Rapid absorption (well-vascularized)
- Lidocaine, tetracaine, benzocaine, cocaine
- Uses: Airway instrumentation, urethral catheterization, endoscopy

**Intact Skin**:
- EMLA cream (lidocaine + prilocaine)
- Requires occlusive dressing, 60-120 min

**Eutectic Mixtures**:
- EMLA: Lidocaine 2.5% + prilocaine 2.5%
- Eutectic point: Both drugs liquid at room temp → better penetration
- Methemoglobinemia risk (prilocaine) in infants

### Infiltration Anesthesia

**Technique**: Direct injection into tissue

**Uses**: Minor surgery, laceration repair, dental

**Agents**: Lidocaine (most common), bupivacaine (longer), mepivacaine

**Tips**:
- Use small gauge needle (27-30G) to minimize pain
- Inject slowly
- Warm solution, alkalinize (↓pain)
- Massage to spread

### Field Block

**Technique**: Inject around area (not directly into it)

**Uses**: Scalp laceration, hernia repair

**Advantage**: Avoids distorting anatomy, cleaner field

### Nerve Blocks

**Peripheral Nerve Blocks**:
- Target specific nerve or plexus
- Examples:
  - **Upper extremity**: Interscalene, supraclavicular, axillary
  - **Lower extremity**: Femoral, sciatic, popliteal, ankle
  - **Truncal**: Intercostal, paravertebral, TAP block
  - **Head/Neck**: Scalp blocks, dental blocks

**Agents**: 
- Short procedures: Lidocaine, mepivacaine
- Long procedures/analgesia: Bupivacaine, ropivacaine

**Adjuvants**: Epinephrine, dexamethasone (prolongs duration)

### Intravenous Regional Anesthesia (Bier Block)

**Technique**:
1. Exsanguinate limb (elevation, Esmarch bandage)
2. Apply double tourniquet (proximal limb)
3. Inflate tourniquet above systolic pressure
4. Inject local anesthetic IV (distal to tourniquet)
5. Anesthetic distributes in venous system → diffuses to nerves
6. Keep tourniquet inflated minimum 20 min (prevent sudden systemic release)

**Agents**: Lidocaine 0.5% (3 mg/kg), prilocaine (safer)

**Uses**: Hand, foot, forearm surgery

**Contraindications**: 
- Sickle cell disease
- Severe peripheral vascular disease
- Tourniquet intolerance

**Risks**: Tourniquet failure → sudden systemic toxicity

### Spinal Anesthesia (Subarachnoid Block)

**Technique**: 
- Inject into CSF (subarachnoid space)
- Level L3-L4 or L4-L5 (below spinal cord terminus at L1-L2)

**Agents**:
- **Lidocaine** 5% (hyperbaric): 40-100 mg
  - **Transient Neurologic Symptoms (TNS)** common (~15-30%)
  - Cauda equina syndrome risk (high concentrations)
- **Bupivacaine** 0.5-0.75% (hyperbaric or isobaric): 5-20 mg
- **Tetracaine**: 5-20 mg (longest duration)
- **Ropivacaine**: 10-20 mg

**Baricity**:
- **Hyperbaric**: Specific gravity > CSF (add dextrose) → settles with gravity
- **Isobaric**: Same as CSF → spreads along injection level
- **Hypobaric**: Specific gravity < CSF → rises

**Duration**:
- Lidocaine: 1-1.5 hours
- Bupivacaine: 2-4 hours
- Tetracaine: 2.5-5 hours

**Dermatomal Level**:
- **T10**: Umbilicus (appendectomy, cesarean)
- **T4**: Nipples (upper abdominal surgery)
- **Position and baricity** determine spread

**Adverse Effects**:
- **Hypotension** (sympathetic blockade)
- **Bradycardia** (high block → T1-T4 cardioaccelerator fibers)
- **Post-dural puncture headache (PDPH)**: CSF leak
  - Worse upright, better supine
  - Treatment: Bed rest, fluids, caffeine; epidural blood patch
- **High/total spinal**: Respiratory paralysis (emergency)

**Contraindications**:
- Patient refusal
- Infection at injection site
- Coagulopathy, anticoagulation
- Hypovolemia/shock
- Increased ICP (relative)

### Epidural Anesthesia

**Technique**: Inject into epidural space (outside dura)

**Agents**:
- **Chloroprocaine** 3%: Fast onset, safe (obstetrics)
- **Lidocaine** 2%: Intermediate
- **Bupivacaine** 0.5-0.75%: Long, motor block
- **Ropivacaine** 0.2-0.75%: Sensory > motor (analgesia)

**Volumes**: Larger than spinal (15-30 mL vs. 2-4 mL)

**Uses**:
1. **Labor analgesia**: Bupivacaine or ropivacaine 0.0625-0.125% + fentanyl
2. **Surgical anesthesia**: Higher concentrations
3. **Postoperative analgesia**: Epidural catheter, continuous infusion

**Advantages over Spinal**:
- Catheter placement → continuous/prolonged anesthesia
- Titratable (incremental dosing)
- Less hypotension (slower onset)

**Adverse Effects**:
- **Unintentional dural puncture**: "Wet tap" → PDPH
- **Intravascular injection**: Test dose (epinephrine) to detect
- **High/total epidural**: Similar to high spinal
- **Epidural hematoma**: Risk with anticoagulation
- **Epidural abscess**: Rare

**Test Dose**:
- 3 mL lidocaine 1.5% with epinephrine 1:200,000 (15 mcg epi)
- Intravascular: ↑HR, palpitations within 60 sec
- Subarachnoid: Rapid onset of spinal anesthesia

**Contraindications**: Similar to spinal

---

## Systemic Toxicity

### Local Anesthetic Systemic Toxicity (LAST)

**Pathophysiology**: High plasma levels → effects on CNS and cardiovascular system

**Causes**:
- Intravascular injection (most common)
- Excessive dose
- Rapid absorption from highly vascular area
- Repeated dosing without allowing clearance

**Plasma Level and Toxicity**:
```
<5 mcg/mL: Therapeutic/safe
5-10 mcg/mL: CNS symptoms (early)
10-20 mcg/mL: Seizures
>20 mcg/mL: Cardiovascular collapse
```

**Order of Susceptibility to Toxicity** (most to least toxic):
1. **Bupivacaine** (most cardiotoxic)
2. Levobupivacaine, ropivacaine (less than bupivacaine)
3. Lidocaine, mepivacaine
4. Chloroprocaine (least toxic - rapid metabolism)

**CNS Toxicity** (occurs before cardiac at lower levels):

**Progression**:
1. **Early Signs** (5-10 mcg/mL):
   - Circumoral numbness, tongue paresthesias
   - Metallic taste
   - Tinnitus
   - Lightheadedness, dizziness
   - Visual disturbances

2. **Excitatory Phase** (10-15 mcg/mL):
   - Agitation, restlessness
   - Muscle twitching
   - Shivering
   - **Seizures** (generalized tonic-clonic)

3. **Depressive Phase** (>20 mcg/mL):
   - CNS depression
   - Respiratory arrest
   - Coma

**Mechanism**: 
- Inhibition of inhibitory pathways → initial excitation (seizures)
- Then generalized CNS depression

**Cardiovascular Toxicity** (higher plasma levels than CNS):

**Myocardial Effects**:
- Negative inotropy (↓contractility)
- Negative chronotropy (↓HR)
- Negative dromotropy (↓conduction)

**Electrophysiologic Effects**:
- Prolonged PR, QRS, QT intervals
- AV block
- **Ventricular arrhythmias**: VT, VF
- **Asystole**

**Vascular Effects**:
- Vasodilation → hypotension (high levels)

**Bupivacaine Cardiotoxicity**:
- **Most cardiotoxic** local anesthetic
- Rapid, profound cardiovascular collapse
- **Difficult to resuscitate**
- Binds cardiac Na+ channels tightly (slow dissociation)
- **Pregnancy**: Even more susceptible (progesterone effects)

### Treatment of LAST

**ASRA (American Society of Regional Anesthesia) Guidelines**:

**1. Stop Injection** (if ongoing)

**2. Call for Help** (LAST cart)

**3. Airway Management**:
- **100% oxygen**
- **Control seizures** (prevent hypoxia, acidosis)
  - Benzodiazepines (midazolam 1-2 mg IV, lorazepam 1-2 mg)
  - Avoid propofol (may worsen cardiovascular depression)
- **Intubate if necessary**

**4. Lipid Emulsion Therapy** (CORNERSTONE of treatment):

**20% Lipid Emulsion (Intralipid)**:
- **Bolus**: 1.5 mL/kg IV over 1 min (100 mL for 70 kg)
- **Infusion**: 0.25 mL/kg/min (continue for at least 10 min after circulatory stability)
- **Repeat boluses**: q 5 min x 2 if persistent cardiovascular collapse
- **Maximum dose**: 10 mL/kg over 30 min

**Mechanism**:
- "Lipid sink": Lipophilic local anesthetic partitions into lipid phase → ↓free drug
- Improved cardiac metabolism/contractility
- Reverses mitochondrial toxicity

**Indications**:
- Seizures refractory to benzodiazepines
- Cardiac arrest or arrhythmias
- Severe hypotension

**5. ACLS with Modifications**:
- **Epinephrine**: Small doses (<1 mcg/kg)
  - Large doses may overwhelm compromised myocardium
- **Vasopressin**: Avoid (may worsen pulmonary hypertension)
- **Amiodarone**: Preferred antiarrhythmic
- **Lipid infusion** takes priority
- **Prolonged resuscitation** (>60 min) may be needed
- **Cardiopulmonary bypass/ECMO** if available and refractory

**6. Avoid**:
- Propofol (lipid-based, may worsen cardiovascular depression)
- Calcium channel blockers
- Beta-blockers
- Local anesthetic test doses containing epinephrine during resuscitation

**Prevention**:
- Use lowest effective dose
- Aspiration before injection (check for blood)
- Incremental dosing (fractionate large doses)
- Use epinephrine test dose (detect IV injection)
- Continuous communication with patient
- Use ultrasound guidance when possible

---

## Other Adverse Effects

### Methemoglobinemia

**Agents**: Prilocaine, benzocaine (most common)

**Mechanism**: 
- Metabolites (o-toluidine from prilocaine) oxidize Fe2+ → Fe3+ (methemoglobin)
- Methemoglobin cannot bind oxygen

**Risk Factors**:
- High doses
- G6PD deficiency
- Infants (immature enzyme systems)
- Concurrent oxidizing drugs (dapsone, nitrates)

**Clinical Features**:
- **Cyanosis** unresponsive to oxygen (chocolate-brown blood)
- Dyspnea, fatigue
- Severe: Altered mental status, seizures, coma

**Diagnosis**: 
- Co-oximetry (measures methemoglobin directly)
- Oxygen saturation gap (pulse ox low, PaO2 normal)

**Treatment**:
- **Methylene blue** 1-2 mg/kg IV over 5 min
  - Reduces methemoglobin back to hemoglobin
- **Contraindicated** in G6PD deficiency (can worsen hemolysis)
  - Use ascorbic acid instead

### Allergic Reactions

**True Allergy**: Rare (<1%)

**Esters > Amides**:
- Esters: PABA metabolite (allergenic)
- Cross-reactivity between esters
- Amides: Usually due to preservatives (methylparaben)

**Types**:
- Type I (IgE-mediated): Urticaria, angioedema, anaphylaxis
- Type IV (delayed hypersensitivity): Contact dermatitis

**Differential Diagnosis** (more common than true allergy):
- **Vasovagal reaction** (syncope, bradycardia)
- **Epinephrine reaction** (anxiety, tachycardia, palpitations)
- **Intravascular injection** (CNS symptoms)

**Management**:
- True allergy: Avoid class, use alternative (amide if ester allergy)
- If uncertain: Allergy testing (skin testing, graded challenge)
- Preservative-free formulations may be tolerated

### Neural Toxicity

**Transient Neurologic Symptoms (TNS)**:
- Associated with **spinal lidocaine** (5% hyperbaric)
- Pain/dysesthesia in legs/buttocks 24-48h after spinal
- Resolves spontaneously in days to weeks
- Mechanism unknown
- **Lidocaine >> bupivacaine, ropivacaine**

**Cauda Equina Syndrome**:
- Rare, permanent injury
- Associated with high-concentration local anesthetics in spinal space
- Microcatheters (increased pooling)
- Avoid continuous spinal lidocaine >100 mg

**Peripheral Nerve Injury**:
- Intraneural injection (needle trauma)
- Direct neurotoxicity (rare)
- Ischemia (epinephrine in nerve block)

---

## Clinical Pearls

1. **Amides have two "i"s in name**: Lidocaine, bupivacaine, mepivacaine
2. **Never use epinephrine in digits**: Risk of ischemia (ears, nose, penis, toes)
3. **Bupivacaine is most cardiotoxic**: Difficult to resuscitate; avoid 0.75% in obstetrics
4. **Lipid emulsion for LAST**: 20% intralipid 1.5 mL/kg bolus
5. **Lidocaine for arrhythmias**: Ventricular tachycardia, VF
6. **pKa and onset**: Lower pKa → faster onset (lidocaine 7.7)
7. **Protein binding and duration**: Higher binding → longer duration (bupivacaine 95%)
8. **Methemoglobinemia**: Prilocaine, benzocaine; treat with methylene blue
9. **EMLA requires 60-120 min**: Plan ahead for procedures
10. **Chloroprocaine safest in pregnancy**: Rapid ester hydrolysis
11. **Cocaine only LA with vasoconstrictor**: Blocks NE reuptake
12. **TNS with spinal lidocaine**: Pain in legs/buttocks, self-limited
13. **Differential nerve block**: Small pain fibers blocked before large motor fibers
14. **Alkalinization speeds onset**: Add bicarbonate (↑uncharged form)
15. **Use-dependent block**: More block with rapid firing (pain neurons)

---

## Key Takeaways

1. **Local anesthetics block voltage-gated Na+ channels** → prevent action potential propagation
2. **Amides metabolized in liver; esters by plasma cholinesterase**
3. **Lipid solubility determines potency**: Bupivacaine > lidocaine > procaine
4. **pKa determines onset**: Lower pKa → faster (lidocaine fastest amide)
5. **Protein binding determines duration**: Higher binding → longer (bupivacaine longest)
6. **Epinephrine prolongs duration, reduces toxicity**: NEVER in digits
7. **LAST treatment**: Airway, seizure control, **lipid emulsion**, ACLS
8. **Bupivacaine most cardiotoxic**: Rapid CV collapse, difficult resuscitation
9. **Differential block**: Pain/temperature lost before motor function
10. **Methemoglobinemia**: Prilocaine, benzocaine; treat with methylene blue

---

## References

1. Miller's Anesthesia, 9th Edition
2. Cousins & Bridenbaugh's Neural Blockade, 4th Edition
3. ASRA Practice Advisory on Local Anesthetic Systemic Toxicity
4. Katzung's Basic & Clinical Pharmacology, 15th Edition
5. American Society of Regional Anesthesia and Pain Medicine (ASRA) Guidelines
